Surgery Partners, Inc. Announces Expiration and Results of Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032
Surgery Partners secures consents to amend $1.225 billion notes ahead of merger closing.
What the company is saying
Surgery Partners, Inc. (NASDAQ:SGRY) is announcing that holders of its $1,225,000,000 aggregate principal amount of 7.250% Senior Notes due 2032 have provided the requisite consents to amend the indenture governing these notes. The company emphasizes that the consent solicitation process, which expired at 5:00 p.m. New York City time on November 20, 2026, was successful and that the amendments are specifically tied to the pending merger with Spyglass Topco, LLC and Bon Secours Mercy Health, Inc. The narrative is procedural, focusing on the mechanics and legal requirements of the consent process, and clarifies that all other terms of the notes—including principal, interest, and maturity—remain unchanged. The company highlights the payment of a $5.00 per $1,000 principal Consent Fee to holders who participated, with payment expected on November 24, 2026, regardless of whether the merger is completed. The announcement also details the next steps: execution of a supplemental indenture and the conditions under which the amendments become operative. The tone is factual and neutral, with no forward-looking claims about operational or financial synergies.
What the data suggests
The company has $1,225,000,000 in outstanding 7.250% Senior Notes due 2032, which are the subject of the consent solicitation. The consent process concluded on November 20, 2026, and the company received the required consents to proceed with the proposed amendments. Holders who validly consented will receive a cash payment of $5.00 per $1,000 in principal, with payment expected on November 24, 2026. The amendments to the indenture are narrowly focused: they expand the definition of 'Permitted Holders' to include BSMH, HealthSpan Partners, and affiliates, contingent on the merger closing on or before five business days after the End Date as defined in the merger agreement. No changes are being made to the principal, interest rate, or maturity of the notes. If the merger does not close within the specified timeframe, the amendments will not become operative, but holders who received the Consent Fee will keep it. The data is complete for the transaction mechanics but does not address operational or financial performance.
Analysis
The announcement is a factual update on the results of a consent solicitation related to a $1.225 billion note issue and a pending merger. The language is procedural and legalistic, with no promotional or exaggerated claims about future benefits or operational synergies. While several statements are forward-looking (e.g., the merger's completion, amendments becoming operative), these are described as contingent steps rather than guaranteed outcomes, and the mechanics and conditions are clearly spelled out. There is no attempt to frame the transaction as immediately value-accretive or transformative, nor are there any claims about future financial performance. The only capital intensity signal is the large principal amount of the notes and the context of a major merger, but the announcement does not hype the potential returns or benefits. No profitability, revenue, or operational metrics are disclosed, but this is appropriate for a legal/transactional update. The gap between narrative and evidence is minimal.
Risk flags
- ●The effectiveness of the proposed amendments is entirely dependent on the timely consummation of the merger. If the merger does not close on or before five business days after the End Date, the amendments will not become operative, creating uncertainty for noteholders regarding the final terms of the indenture.
- ●There is a risk that holders who consented and received the Consent Fee may face a scenario where the amendments do not take effect, but the fee is retained, potentially leading to misalignment between incentives and outcomes.
- ●The announcement references significant transaction costs and the potential for competing offers or regulatory delays, which could disrupt or delay the merger and the associated amendments to the note indenture.
- ●The process involves multiple parties and amendments to complex legal agreements, increasing the risk of execution delays or unforeseen legal or regulatory complications that could impact both the merger and the noteholder amendments.
Bottom line
Surgery Partners has completed the consent solicitation process to amend the indenture on $1.225 billion of 7.250% Senior Notes due 2032, clearing a key procedural hurdle ahead of its planned merger with Spyglass Topco, LLC and Bon Secours Mercy Health, Inc. The amendments are narrowly tailored to facilitate the merger, specifically by expanding the list of 'Permitted Holders' under the indenture, and do not affect the principal, interest rate, or maturity of the notes. Holders who participated will receive a $5.00 per $1,000 principal Consent Fee, regardless of whether the merger closes, but the amendments themselves only become operative if the merger is completed within a short, defined window. The announcement is transparent about mechanics and conditions but does not provide any operational or financial performance data. The most important takeaway is that this is a procedural step in a larger M&A process, with the ultimate outcome still contingent on successful and timely merger execution.
Track record
NewsStack has analysed 4 announcements from SGRY since May 2026.
Previous SGRY verdicts
- 18 Nov 2026Routine NoiseSurgery Partners, Inc. Announces Increased Consent Fee in Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032
- 16 Nov 2026Routine NoiseSurgery Partners, Inc. Announces Commencement of Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032
- 5 May 2026Likely OverhypedSurgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance
Announcement summary
(NASDAQ:SGRY) Surgery Partners, Inc. announced the results of the previously announced solicitation of consents (the “Consent Solicitation”) by its indirect wholly owned subsidiary, Surgery Center Holdings, Inc., from holders of its outstanding $1,225,000,000 aggregate principal amount of 7.250% Senior Notes due 2032 (CUSIP Nos. 86881W AF9 / U86786 AD9 / U86786 AE7; ISINs US86881WAF95 / USU86786AD98 / USU86786AE71). The Consent Solicitation was made pursuant to the Consent Solicitation Statement dated November 16, 2026, as amended, and expired at 5:00 p.m., New York City time, on November 20, 2026. As of the Expiration Time, the Issuer had received the requisite consents to effect the Proposed Amendments to the indenture governing the Notes. On October 23, 2026, Surgery Partners entered into an Agreement and Plan of Merger with Spyglass Topco, LLC, Spyglass Merger Subsidiary, Inc., and Bon Secours Mercy Health, Inc. (BSMH), as amended. Pursuant to the Merger Agreement, Merger Sub will merge with and into Surgery Partners, with Surgery Partners surviving as a wholly owned subsidiary of Topco. The Proposed Amendments will amend the Indenture to provide that, concurrently with and following the consummation of the Merger on or prior to the date that is five business days after the End Date, each of BSMH, HealthSpan Partners (a 501(c)(3) Ohio corporation affiliated with BSMH), and their respective affiliates, and certain groups of which any of them are members, will be “Permitted Holders” under the Indenture, in addition to the existing Permitted Holders. The Proposed Amendments will also add to, amend, supplement or change certain other defined terms in the Indenture related to the foregoing. All existing terms of the Notes and the Indenture will remain unchanged except for the Proposed Amendments, and the Proposed Amendments will not alter the Issuer’s obligation to pay the principal of or interest on the Notes or the stated interest rate or maturity date of the Notes. The Issuer intends to execute a supplemental indenture setting forth the Proposed Amendments on or around November 24, 2026. The Supplemental Indenture will become effective upon its execution and delivery, but the Proposed Amendments will become operative only immediately prior to the consummation of the Merger, provided that the Consent Fee has been paid. Once operative, the Proposed Amendments will be binding on all Holders, including those that did not deliver consents. If the Consent Fee is paid but the Merger is not consummated on or prior to the date that is five business days after the End Date, the Proposed Amendments will not become operative, and Holders that received the Consent Fee will retain it. Holders who validly delivered (and did not validly revoke) consents prior to the Expiration Time will receive a cash payment equal to $5.00 per $1,000 in principal amount of Notes for which such consents were delivered. The Issuer expects to pay the Consent Fee on November 24, 2026, whether or not the Merger is consummated. Jefferies LLC acted as solicitation agent and S&P Global Inc. acted as information and tabulation agent in connection with the Consent Solicitation. Surgery Partners will file a proxy statement and a transaction statement on Schedule 13E-3 with the SEC in connection with the proposed acquisition by an affiliate of BSMH. The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies from the Company’s stockholders in connection with the proposed Transactions. Additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed Transactions will be set forth in the Proxy Statement and Schedule 13E-3 and other relevant materials to be filed with the SEC.
Disagree with this article?
Ctrl + Enter to submit